Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089856 · ClinicalTrials.gov registry record · Phase 3
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
A Phase 3 study, sponsored by Cell Genesys.
- Terminated
- Registry status
- Phase 3
- Development phase
- 626
- Enrollment target
NCT00089856: Clinical Trial Phase 3 study, sponsored by Cell Genesys.
NCT00089856 is a Phase 3 study that was terminated before completion, run by Cell Genesys. The registered enrollment target is 626 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089856, a Phase 3 study, was terminated before completion, sponsored by Cell Genesys.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 626 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.
Interventions
- BIOLOGICAL Immunotherapy with allogeneic prostate vaccine
- DRUG Chemotherapy (Taxotere and prednisone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 626 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089856
The ClinicalTrials.gov registry entry for NCT00089856 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 626 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cell Genesys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Immunotherapy with allogeneic prostate vaccine is the first listed.
NCT00089856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089856 about?
NCT00089856 is a clinical study titled "GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer". The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in th...
What is the current status of trial NCT00089856?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 626 participants. The study started on 2004-07. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00089856?
The interventions under investigation include: Immunotherapy with allogeneic prostate vaccine (BIOLOGICAL), Chemotherapy (Taxotere and prednisone) (DRUG).
Who is sponsoring clinical trial NCT00089856?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.